Celecoxib

Licensed by Pfizer 製品コードS1261 別名:SC 58635

Celecoxib化学構造

分子量(MW):381.37

セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。

サイズ 価格 在庫  
JPY 13966.83 あり
JPY 38876.76 あり

カスタマーフィードバック(3)

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

製品安全説明書

COX阻害剤の選択性比較

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
ターゲット
COX-2 [1]
(Sf9 cells)
40 nM
体外試験

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NXLEc2ZXTnWwY4Tpc44hSXO|YYm= MVuwMlEuOzBizszN NHzibGo1QCCq NV;m[oROcW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx? M3\HOlI3PTF|MUey
H460 MYHGeY5kfGmxbjDBd5NigQ>? NFXwOXUxNjFvM{Cg{txO M2HWV|Q5KGh? NH;odFBqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? M2S3ZlI3PTF|MUey
HKESC-2 M2XQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqyNOKh|ryP M17meFQ5yqCqwrC= M1TPdpNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? MUCyOlQ4PDZ7Mx?=
CaES-17 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;DV|IxyqEQvF2= NYfnWWw3PDkEoHlCpC=> MWXzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> M3K4U|I3PDd2Nkmz
HKESC-2 MWnBdI9xfG:|aYOgRZN{[Xl? M4XqT|IxyqEQvF2= M{\VWVQ5yqCqwrC= MlPrdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NGP5OHczPjR5NE[5Ny=>
CaES-17 MVrBdI9xfG:|aYOgRZN{[Xl? Mn\ENlDDqM7:TR?= NXLkRYJOPDkEoHlCpC=> NXW1bIxyemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>? M{S1PFI3PDd2Nkmz
A549 NULDN3JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnmOlU4PS1zNkCg{txO M2e5elQ5yqCqwrC= NWDrZpBzTE2VTx?= NWLEbVN2UUN3ME2xOlMvPCEQvF2= M1rDfFI3PDZ2NkSz
HCC827 MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PRVFUuOTZyIN88US=> Ml;LOFjDqGkEoB?= M{W3dmROW09? NH\HSZBKSzVyPU[5MlIh|ryP NF72UVczPjR4NE[0Ny=>
A549 MkfvRZBweHSxc3nzJGF{e2G7 MlzUPFAhyrWP NULYbYlwPDkEoHlCpC=> MoLoSG1UVw>? NH;iWIpqdmS3Y3XzJIFxd3C2b4Ppdy=> M33RZVI3PDZ2NkSz
HCC827 NGK5UWxCeG:ydH;zbZMhSXO|YYm= M1PLflgxKML3TR?= NYK3UY5YPDkEoHlCpC=> MV7EUXNQ M{PodYlv\HWlZYOgZZBweHSxc3nz NYTL[3NHOjZ2NkS2OFM>
SGC-7901/DDP NHHjbXRHfW6ldHnvckBCe3OjeR?= MVyxNOKhyrWP MkX0NlQhcA>? MXzpcohq[mm2czDjfYNtd2:6eXflcoF{\S1{IHHu[EBRNWeueXPvdJJwfGWrbjDlfJBz\XO|aX;u M3m4clI3PDB5NkWz
SGC-7901  NX;XfVF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTuWHozPMLiaNMg MV7JR|UxRTFzNT6wPEDPxE1? Mnj3NlY1ODd4NUO=
SGC-7901/DDP M1juVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOyOOKhcMLi MWHJR|UxRTN3LkS1JO69VQ>? MWmyOlQxPzZ3Mx?=
SGC-7901/DDP MnftRZBweHSxc3nzJGF{e2G7 NFexd4MyOMLiwsXN M2fRZ|I1KGh? NXrVPZdHcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDD3bZRpKGOrc4DsZZRqdg>? M{DYUVI3PDB5NkWz
SGC-7901/DDP NHXHTphHfW6ldHnvckBCe3OjeR?= NF2xTHYyOMLiwsXN NFHIZYczPCCq NYDOSlhncW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC= M1K5UVI3PDB5NkWz
SGC-7901/DDP NXjrOmRlTnWwY4Tpc44hSXO|YYm= MkewNVDDqML3TR?= NHvRcnYzPCCq MljPZ4F2e2W|IHGgcYFzc2WmIHTlZ5Jm[XOnIHnuJJRp\SCuZY\lcEBw\iCEY3ytNkBxem:2ZXnu MlXiNlY1ODd4NUO=
H357 NEX4Z4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPwRmpwPy53L{GwJO69VQ>? MWG0PEBp NWrJXW1yTE2VTx?= MVXpcohq[mm2czDj[YxtKGe{b4f0bOKh[2:vYnnu[YQhf2m2aDDTZYJ2fG:lbHH4 NYTJXoo{OjZyMEm4O|Q>
TAF NIfPcYhHfW6ldHnvckBCe3OjeR?= NXraZlU{OTEEoNM1US=> NFW0Slk4KGR? NXf0fFdr[W[oZXP0d{BVSU[|IHHkbIV{cX[nIIDyc5BmenSrZYO= NYXtUmlwOjV7OEexNlc>
TAF NGrTcIxHfW6ldHnvckBCe3OjeR?= MkD6NVDDqML3TR?= NHXZfGo{OC1zMkCgcYlv NITGcXJxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc> NHH3NZMzPTl6N{GyOy=>
TAF NWnwfZpPTnWwY4Tpc44hSXO|YYm= MXexNOKhyrWP NE[3[Gw1QCCq M3fu[olv[3KnYYPld{BGT0[UIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MkHaNlU6QDdzMke=
PANC-1 NV6w[XB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWyNE83OC9zMECg{txO MoL3NlQwPDhxN{KgbC=> NFfmeVdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3zhR|I2QTd|ME[y
PANC-1 M1rEemZ2dmO2aX;uJGF{e2G7 NGnTe3UzOC94MD:xNFAh|ryP MVOyOEBp NX7qNmJt[XS2ZX71ZZR{KGOnbHygbY53[XOrb36gZY5lKG2rZ4LheIlwdiCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MX6yOVk4OzB4Mh?=
HeLa  MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP1Unp4OjEEoN88UeKh MonlNlTDqGh? NYTRb3VI\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= MVGyOVc4ODR{Mx?=
SACC-83 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL5NlDDqM7:TdMg NXfyfnp7OjUEoHi= Mk\G[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? M2W4WVI2PzdyNEKz
HeLa  NUe3RW55SXCxcITvd4l{KEG|c3H5 NVrOeph2OjEEoN88UeKh MkPNNlTDqGh? NXv3eo0z\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? NXvEVWdGOjV5N{C0NlM>
SACC-83 M{fv[WFxd3C2b4Ppd{BCe3OjeR?= M{n4NFIxyqEQvF5CpC=> NYHCN4ZKOjUEoHi= MoCz[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> MkPZNlU4PzB2MkO=
HeLa  MWjGeY5kfGmxbjDBd5NigQ>? MX6yNE81OC96MDFOwG0> NFPwcYwzPMLiaB?= NVztcpZKfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? MkX0NlU4PzB2MkO=
SACC-83 MnT1SpVv[3Srb36gRZN{[Xl? NVXNXlRiOjBxNECvPFAh|ryP MoWwNlTDqGh? MUL1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> MoDRNlU4PzB2MkO=
HLCZ01 M1f6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOw5qCUPjEEoNM1US=> MnrYOFghcA>? NYS3b4pXTE2VTx?= NY\wUG95cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MV[yOVczPDh7OR?=
HLCZ01 M1HScmZ2dmO2aX;uJGF{e2G7 MnvLOFDDqM7:TR?= M2jwNVI1KGh? NFj1ZnNFVVOR MlnnbY5kemWjc3XzJIFk[3WvdXzheIlwdiCxZjDHNE9IOS2yaHHz[UBk\WyuczDjc41jcW6nZDD3bZRpKEmITj5OtS=> MXmyOVczPDh7OR?=
HLCZ01 M1TIdWFxd3C2b4Ppd{BCe3OjeR?= M{DubVQxyqEQvF2= M3znWlI1KGh? M{HlNWROW09? NYPDO|Fv\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z MofrNlU4OjR6OUm=
HLCZ01 NGS1OndHfW6ldHnvckBCe3OjeR?= MkH6OFDDqM7:TR?= NHywRmIzPCCq Mm\NSG1UVw>? M4XidYlv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> MWOyOVczPDh7OR?=
MGC803 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\M[|AuPjBizszN M37P[FczKGh? MnO3TWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= NULnSIM4OjV5MEGzO|g>
SGC7901 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVewMVYxKM7:TR?= MlW4O|IhcA>? M1e5SmlEPTB;NEOuOVPjiIoEsfMAjVUvOTJizszN MmrSNlU4ODF|N{i=
MGC803 M1TIbWZ2dmO2aX;uJGF{e2G7 NFjHVII1OMLizszN M1W1[|gwOTZxMkSgbC=> NFHkcox2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44> NULlbot{OjV5MEGzO|g>
SGC7901 M2n2UmZ2dmO2aX;uJGF{e2G7 MnrPOFDDqM7:TR?= NV[0eVVPQC9zNj:yOEBp NY\GS5lFfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v NWrHPYhIOjV5MEGzO|g>
MCF-7  M3fC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGxNU8yOCEQvF2= M2\I[VczKGh? MormSG1UVw>? NYnocoty\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= NX72SINXOjV4Nke1NVA>
MDA-MB-231  M1\FVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjmZ454OS9zMDFOwG0> NFLidnI4OiCq MWXEUXNQ MY\lcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? MXuyOVY3PzVzMB?=
MDA-MB-231 NVLKe5pDTnWwY4Tpc44hSXO|YYm= MoTkNE01OCEEtV2= NIPnOJQ1NTJ2IHi= Mn;qbY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NUfEVWJ3OjV3OEezNlk>
MCF-7 Ml;PSpVv[3Srb36gRZN{[Xl? Mk\yNE01OCEEtV2= NXT3e4cyPC1{NDDo NYLkSYNp\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?= MnuyNlU2QDd|Mkm=
MCF7-MX  NGTlN|RHfW6ldHnvckBCe3OjeR?= M1XQT|AuPDBiwsXN MVG0MVI1KGh? M4f2[YVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? NHTuZWkzPTV6N{OyPS=>
MDA-MB-231 M2LNVmZ2dmO2aX;uJGF{e2G7 NXfSSZpQOC12MDFCuW0> NGHrSJY1NTJ2IHi= NUH3PGdQe3SrbYXsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCDQlPHNkB2eCC2bzC0MlI4KHSrbXXzJJRwKGOxboTyc4whdGW4ZXygZpkhOTJiaNMg NFHuemUzPTV6N{OyPS=>
A2780 NV31TGxQTnWwY4Tpc44hSXO|YYm= NYHhS3JPPS9zMD:xOUDPxE1? NVHHZm17PDhiaB?= Mnr5[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXvGPVZZOjV2MkS4PVg>
SKOV3  NI[xeFhHfW6ldHnvckBCe3OjeR?= MWG1M|ExNzF3IN88US=> MnTiOFghcA>? NHfGT5Fl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{nwTFI2PDJ2OEm4
A2780 MV3GeY5kfGmxbjDBd5NigQ>? MV[1M|ExNzF3IN88US=> NIfNW3M1QCCq Ml3I[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? NVrPe2dNOjV2MkS4PVg>
SKOV3  NYLKOmp4TnWwY4Tpc44hSXO|YYm= NH\wWY82NzFyL{G1JO69VQ>? MVm0PEBp MU\lcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv MXmyOVQzPDh7OB?=
A2780 MVzGeY5kfGmxbjDBd5NigQ>? NIDjc4E2NzFyL{G1JO69VQ>? NXzSb5FRPDhiaB?= NFrsXVFl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= NHTy[3czPTR{NEi5PC=>
SKOV3  MXTGeY5kfGmxbjDBd5NigQ>? M4[y[|UwOTBxMUWg{txO M2PZPFQ5KGh? NFnIbVFl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= NUeyfo1POjV2MkS4PVg>
A2780 NFH2c4ZHfW6ldHnvckBCe3OjeR?= NYjWUWJVPS9zMD:xOUDPxE1? M4DWcFEhcA>? MVXpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Moj6NlU1OjR6OUi=
SKOV3  M2D2fGZ2dmO2aX;uJGF{e2G7 NYnnXmI{PS9zMD:xOUDPxE1? NIDxVo8yKGh? M2m2folv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYG5V4w3OjV2MkS4PVg>
HCT-15 M13lUmZ2dmO2aX;uJGF{e2G7 Mln0NVAuPTBizszN MnnoOk0{PiCq MWrpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ MlTzNlUzOThyMki=
HT-29  M2roNmZ2dmO2aX;uJGF{e2G7 NGnBfnMyOC13MDFOwG0> NIey[m43NTN4IHi= NWWzbmxocW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NVm2RYVmOjV{MUiwNlg>
HSC3  MnywR4VtdCCYaXHibYxqfHliQYPzZZk> NUKwWHE2OOLCk{SwJO69VQ>? M3XTV|Q5KGh? NVP0NHhEUUN3ME2yOU42yrFzLke4NEDPxE1? NFP6S2gzPTF7OEe4PS=>
HSC3  M1jVV2Fxd3C2b4Ppd{BCe3OjeR?= MmrlNlUh|ryP NY\GNlZ6PDhiaB?= NELtbplqdmS3Y3XzJIFxd3C2b4Ppdy=> M{fodFI2OTl6N{i5
HSC3  NUXxWWlOTnWwY4Tpc44hSXO|YYm= NXrxZWFVOjVizszN NVHxSVhNPDhiaB?= MX;lfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV MWGyOVE6QDd6OR?=
HSC3  NWn2VW5ZTnWwY4Tpc44hSXO|YYm= M{THfVI2KM7:TR?= M3PxN|Q5KGh? M2TXXIlvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=> M1z2b|I2OTl6N{i5
HSC3  MU\GeY5kfGmxbjDBd5NigQ>? M1vzPFI2KM7:TR?= MXu3NkBp M4P4ZoRm[3KnYYPld{BOVVBvMjDhcoQhVU2SLUmgdJJwfGWrboRCpC=> NU\C[ZRtOjVzOUi3PFk>
201T  M1[3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\RPFczKGh? M{PWdmROW09? MWrJR|UxRTR6Lk[gxtVO M3Lh[VI2ODV5OUSx
273T MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f1RlczKGh? M1y1NmROW09? NI\xVVlKSzVyPUiwMlUhyrWP M3OyPVI2ODV5OUSx
Hep-2 NHq2R|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr5VYY{OC93MD:xNFAh|ryP NUHhWJdiOTJxMkSvN|YwPDhiaB?= NW[1ZXVuTE2VTx?= NHrTdmFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NHzROmMzPDl7OEW2OC=>
Hep-2 MV3BdI9xfG:|aYOgRZN{[Xl? M{G5dlUxKM7:TR?= NGHFPXAxNTR6IHi= M4TSZWROW09? M{PHfolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy NG\0eWUzPDl7OEW2OC=>
Hep-2 NX;ESIw1TnWwY4Tpc44hSXO|YYm= NXvy[lRqPTBizszN NXnve2p1OC12ODDo M1nrTWROW09? NEPHNY5z\WS3Y3XzJJRp\SC2ZXzvcYVz[XOnIHHjeIl3cXS7IHfyZYR2[WyueR?= M{HJV|I1QTl6NU[0
Hep-2 NU\rSnRZTnWwY4Tpc44hSXO|YYm= NWWzfpExPTBizszN NWX0SIJzOC12ODDo M13XcWROW09? M{CwRYRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIHjUSXJV NV3Hd2s2OjR7OUi1OlQ>
SGC-7901 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXrNVAwPTBxMUCwJO69VQ>? M2PhXFI1NzR6L{eyJIg> Mo\TSG1UVw>? Mme5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGLQfY4zPDl7Mkm1PC=>
MKN-45 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG2W2pIOTBxNUCvNVAxKM7:TR?= NF7ZdZUzPC92OD:3NkBp NWjEfIhNTE2VTx?= NXuxTmY{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NFrnUYozPDl7Mkm1PC=>
SGC-7901 MlPKSpVv[3Srb36gRZN{[Xl? MljKNVAwPTBxMUCwJO69VQ>? M4XwUVQ5KGh? Mn3pSG1UVw>? NELGflVld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Mk\WNlQ6QTJ7NUi=
MKN-45 MUjGeY5kfGmxbjDBd5NigQ>? M1jubFExNzVyL{GwNEDPxE1? MV:0PEBp M1\0PGROW09? M{fVboRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHPCeWwzPDl7Mkm1PC=>
C666-1 MljBR5l1d3SxeHnjbZR6KEG|c3H5 M1rGfVIxNThyIN88US=> MUSyOEBp M{XJSIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> M2DkO|I1QDV2OEO4
CNE-1 MXPDfZRwfG:6aXPpeJkhSXO|YYm= MlHJNlAuQDBizszN NVO2OVYyOjRiaB?= M4jFfYRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NYTi[G0zOjR6NUS4N|g>
CNE-2 NVHWbHEyS3m2b4TvfIlkcXS7IFHzd4F6 NWrhPYZYOjBvOECg{txO MojMNlQhcA>? MUTk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MVmyOFg2PDh|OB?=
C666-1 NVm4O5o{S3m2b4TvfIlkcXS7IFHzd4F6 MnzZOlAh|ryP NHO0XoQ4KGR? NETQSJJmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> NYTWb|BWOjR6NUS4N|g>
CNE-1 MVXDfZRwfG:6aXPpeJkhSXO|YYm= Ml;DOlAh|ryP M3nNSFch\A>? MnX2[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= NHHQVmEzPDh3NEizPC=>
SNU-1041 M3PuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ZWWJVOC12MDFOwG0> M3LRV|Q5KGh? NFjo[Y1qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MofvNlQ3QTJ5MEO=
SNU-1041 MojGSpVv[3Srb36gRZN{[Xl? NHXkPHczOC9|MDFOwG0> M4HYOFQhcA>? M1q1XYlv\HWlZYOg[ZhxemW|c3nvckBw\sLiQ1jPVEwhT1KSN{lCpIFv\MLiWFLQNeKh[XRidHjlJHJPSSCuZY\lcOKh MWiyOFY6OjdyMx?=
SNU-1041 Mm\vSpVv[3Srb36gRZN{[Xl? MX6wMVQxKM7:TR?= NWLQcotQPCCq NXv0d4NOfXBvcnXneYxifGW|IFPIU3DDqGGodHXyJJRz\WG2bXXueEB4cXSqIHjp[4gh[2:wY3XueJJifGmxboO= NF\pe5gzPDZ7MkewNy=>
SGC-7901 NFi3WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\SSHY2OC1zMkWg{txO M{DC[lI1NzR6L{eyJIg> NFfjO25qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{fxSFI1Pjd4M{m0
SGC-7901 NX[zcZU6SXCxcITvd4l{KEG|c3H5 MWexNFAh|ryP NV;6WYJHPzJiaB?= NV33XFRjcW6mdXPld{BieG:ydH;zbZM> M2XSPVI1Pjd4M{m0
SGC-7901 NGW2fnFHfW6ldHnvckBCe3OjeR?= NYG4dVB4PzVxMUCwM|EzPSEQvF2= MnHzNlQwPDhxN{KgbC=> M2r4Zolv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy NHjEVHczPDZ5NkO5OC=>
LMeC  M4DLTWZ2dmO2aX;uJGF{e2G7 M1n0PVIxNzVyIN88US=> NUjYcIVvPDhiaB?= Mo\V[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IIDyc5RmcW5? MkC4NlQ3PTZ5NE[=
CMeC-1 NEXSUJJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV2yNE82OCEQvF2= MkPMOFghcA>? NIq5eoFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NGXZW44zPDZ3Nke0Oi=>
LMeC NFrRdWhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2HsTlIxNzVyIN88US=> NGnQO3E1QCCq Moe1bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MWmyOFY2Pjd2Nh?=
CMeC-1 MXrGeY5kfGmxbjDBd5NigQ>? NVvMNWZJOjBxNUCg{txO NX31RZk4PDhiaB?= MX;pcoR2[2W|IFexMXMh[XK{ZYP0 NFf6WHczPDZ3Nke0Oi=>
LMeC NYDrO|hWTnWwY4Tpc44hSXO|YYm= M1XHSFIxNzVyIN88US=> NX7WT3RQPDhiaB?= Mni3bY5lfWOnczDHNU1UKGG{cnXzeC=> MUeyOFY2Pjd2Nh?=
CMeC-1 M1rXcWZ2dmO2aX;uJGF{e2G7 NXjDVnV{OjBxNUCg{txO MkPrOFghcA>? M17meoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2m3ZlI1PjV4N{S2
LMeC M{LzW2Z2dmO2aX;uJGF{e2G7 Mmq0NlAwPTBizszN M4TIXVQ5KGh? MVzk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnHqNlQ3PTZ5NE[=
CMeC-1 M1fERWZ2dmO2aX;uJGF{e2G7 MnnVNlAwPTBizszN M2S4NFQ5KGh? MnHmbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MVSyOFY2Pjd2Nh?=
LMeC M3TNU2Z2dmO2aX;uJGF{e2G7 NULiOoU5OjBxNUCg{txO MWq0PEBp NXrDTWducW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? MYeyOFY2Pjd2Nh?=
OVCAR-3 NEfBcXRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NG\JRmwyOCEEtV2= M3\hVVEhcA>? M2DLVYVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> MWCyOFUzODJ{Nx?=
OVCAR-3 NEi5eI9CeG:ydH;zbZMhSXO|YYm= Mn3YNVAhyrWP M3v1RVEhcA>? NGnjc4Nxem:vb4Tld{Bx[WOuaYThfIVtNWmwZIXj[YQh[XCxcITvd4l{yqB? MmHvNlQ2OjB{Mke=
OVCAR-3 NYKzXVRpTnWwY4Tpc44hSXO|YYm= MUSxNEDDvU1? MYSxJIg> NWjqVGtS\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> NF7yfW0zPDV{MEKyOy=>
OVCAR-3 M3i1W2Z2dmO2aX;uJGF{e2G7 NFvSfYoyOCEEtV2= NXfxdHk4OSCq MkTE[I94di2{ZXf1cIF1\XNiTl[t{tpDKGGldHn2ZZRqd25iaX7keYNm\CCkeTDwZYNtcXSjeHXs MYCyOFUzODJ{Nx?=
OVCAR-3 M1rnS2Z2dmO2aX;uJGF{e2G7 M{TZS|ExKML3TR?= MmnINUBp MYPpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> NIi3WpAzPDV{MEKyOy=>
CF33 NICz[JhHfW6ldHnvckBCe3OjeR?= MmG2NVAxKM7:TR?= Mm\MNlQhcA>? NWG2Z4V{cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36= MUeyOFUxOzd6Mh?=
CF33 NIXkcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PDZlExNTFyMDFOwG0> MWSwMVQh\A>? MYfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHrhOVQzPDVyM{e4Ni=>
CF33 NVjTN3J7TnWwY4Tpc44hSXO|YYm= NWW5[VZNOTBvMUCwJO69VQ>? NHf4boM1NTJ2IHi= NH7HfFBl\WO{ZXHz[ZMh[2WubIOgbY4hfGinIGOgdIhie2ViYX7kJIlv[3KnYYPld{Bk\WyuczDpckBIOC:JMTDhdpJme3R? NIjGPZozPDVyM{e4Ni=>
LNCaP M2fzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuyM|UwOTBizszN NUPYUVh4QTZiaB?= M{H1SolvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= MVmyOFI6Pjl5OB?=
LNCaP M1zh[GFxd3C2b4Ppd{BCe3OjeR?= NELwU5IzNzVxMUCg{txO MUe5OkBp NVLlRldncW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDheI9zfmG|dHH0bY4> M16wSVI1Ojl4OUe4
PC-3  NGrV[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj3[IMxNTVyIN88US=> MVi0PQKBkWh? NGLXUZpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NXj0OotTOjRzMke4PFI>
PC-3  M4HXfmNmdGxiVnnhZoltcXS7IFHzd4F6 NHm4NWwxNTFyMDFOwG0> NITDXWc4OiCq MVXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2\MSVI1OTJ5OEiy

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
細胞試験: [2]
+ 展開
  • 細胞株: HNE1 and CNE1-LMP1
  • 濃度: 0-75 μM
  • 反応時間: 48 hours
  • 実験の流れ: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • 製剤: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • 投薬量: ≤200 mg/kg
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
体内 順序で溶剤を入れること:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管
in solvent
別名 SC 58635

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • 回答:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX信号経路図

COX Inhibitors with Unique Features

相関COX製品

Tags: Celecoxibを買う | Celecoxib ic50 | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib化学構造 | Celecoxib分子量 | Celecoxib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID